These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 8679306)
21. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536 [TBL] [Abstract][Full Text] [Related]
22. 3TC/AZT: just another combination. GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997 [TBL] [Abstract][Full Text] [Related]
24. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. Lafeuillade A; Tardy JC AIDS Rev; 2003; 5(2):80-6. PubMed ID: 12876897 [TBL] [Abstract][Full Text] [Related]
25. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122 [TBL] [Abstract][Full Text] [Related]
26. An HIV-1 215V mutant shows increased phenotypic resistance to d4T. Pernas M; López-Galíndez C Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778 [TBL] [Abstract][Full Text] [Related]
27. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. Wu S; Liu X; Solorzano MM; Kwock R; Avramis VI J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):1-9. PubMed ID: 8548339 [TBL] [Abstract][Full Text] [Related]
28. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Richman D; Rosenthal AS; Skoog M; Eckner RJ; Chou TC; Sabo JP; Merluzzi VJ Antimicrob Agents Chemother; 1991 Feb; 35(2):305-8. PubMed ID: 1708976 [TBL] [Abstract][Full Text] [Related]
29. Antiretroviral drug resistance. Japour AJ AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787 [TBL] [Abstract][Full Text] [Related]
31. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. Okamoto M; Makino M; Yamada K; Nakade K; Yuasa S; Baba M Antiviral Res; 1996 Jun; 31(1-2):69-77. PubMed ID: 8793010 [TBL] [Abstract][Full Text] [Related]
32. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA; HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011 [TBL] [Abstract][Full Text] [Related]
33. Stavudine selectively induces apoptosis in HIV type 1-infected cells. Hashimoto KI; Tsunoda R; Okamoto M; Shigeta S; Baba M AIDS Res Hum Retroviruses; 1997 Jan; 13(2):193-9. PubMed ID: 9007205 [TBL] [Abstract][Full Text] [Related]
34. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000 [TBL] [Abstract][Full Text] [Related]
35. Combined effect of C-reactive protein and stavudine on adipogenesis. Stankov MV; Schmidt RE; Behrens GM Antivir Ther; 2009; 14(6):819-29. PubMed ID: 19812444 [TBL] [Abstract][Full Text] [Related]
36. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822 [TBL] [Abstract][Full Text] [Related]
37. [To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry]. Zhou X; Yu W; Li T; Guo F; Lin Q; Shao H; Tian J; Xu Y; Sun P Zhonghua Nei Ke Za Zhi; 2014 Aug; 53(8):622-5. PubMed ID: 25376824 [TBL] [Abstract][Full Text] [Related]
38. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543 [TBL] [Abstract][Full Text] [Related]
39. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745 [TBL] [Abstract][Full Text] [Related]
40. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol. St Clair MH; Pennington KN; Rooney J; Barry DW J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]